Two recent Phase 2b studies, published in The Lancet Infectious Diseases on July 8, 2025, assessed the potential of new oxazolidinones- sutezolid and delpazolid as safer alternatives to linezolid for treating drug-resistant tuberculosis. 

The PanACEADECODE01 trial, conducted in Tanzania and South Africa, involved 76 participants and demonstrated that incorporating a 1,200 mg dose of delpazolid into a regimen with bedaquiline, delamanid, and moxifloxacin over 16 weeks improved efficacy without causing serious adverse effects, with only one mild drug-related incident reported. 

Concurrently, the PanACEASUDOCU01 trial, which included 75 patients, indicated that sutezolid was safe and microbiologically effective at all tested doses, with only two related adverse events and no cases of peripheral or optic neuropathy, anemia, or lactic acidosis. 

Researchers emphasize that if these drugs are validated in larger Phase 3 trials, including those with HIV-positive patients, they could significantly reduce the toxicity associated with linezolid.